DADC
ELOS

D.A. Davidson & Co’s Syneron Medical Ltd ELOS Stock Holding History

D.A. Davidson & Co’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500
Closed -$5K – 2343
2017
Q2 		$5K Hold
500
– – ﹤0.01% 2215
2017
Q1 		$5K Hold
500
– – ﹤0.01% 2190
2016
Q4 		$4K Hold
500
– – ﹤0.01% 2300
2016
Q3 		$3K Hold
500
– – ﹤0.01% 2274
2016
Q2 		$3K Hold
500
– – ﹤0.01% 2228
2016
Q1 		$3K Hold
500
– – ﹤0.01% 2133
2015
Q4 		$3K Hold
500
– – ﹤0.01% 2109
2015
Q3 		$3K Hold
500
– – ﹤0.01% 2088
2015
Q2 		$5K Hold
500
– – ﹤0.01% 2022
2015
Q1 		$6K Hold
500
– – ﹤0.01% 1903
2014
Q4 		$4K Hold
500
– – ﹤0.01% 1970
2014
Q3 		$5K Hold
500
– – ﹤0.01% 1945
2014
Q2 		$5K Hold
500
– – ﹤0.01% 1938
2014
Q1 		$6K Hold
500
– – ﹤0.01% 1910
2013
Q4 		$6K Buy
+500
New +$5.2K ﹤0.01% 1836

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

D.A. Davidson & Co's ELOS Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Syneron Medical Ltd (ELOS) in Q3 2017, closing a stake of 500 shares — an estimated $5K sold.

D.A. Davidson & Co first reported a position in ELOS in Q4 2013 and held it in 15 quarters. The position peaked at $6K in Q1 2015. 4 funds tracked by Wall St. Rank hold ELOS as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Syneron Medical Ltd position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 500 Syneron Medical Ltd shares in Q3 2017, an estimated $5K.
  • D.A. Davidson & Co first reported a position in Syneron Medical Ltd in Q4 2013 and held it in 15 quarters.
  • D.A. Davidson & Co's Syneron Medical Ltd position peaked at $6K in Q1 2015.
  • 4 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.